ProFactor Pharma makes breakthrough in bid to end haemophilia drug shortage

Edinburgh life sciences firm ProFactor Pharma (PFP) has secured the £1.1 million second part of a funding round after its research into haemophilia treatment surpassed expectations.

Investment syndicate Kelvin Capital led the round with support from Ingenza Ltd and the Scottish Investment Bank, the investment arm of Scottish Enterprise.

Read more HERE.